Q1: 2026-05-07 Earnings Summary
EPS of -$0.40 beats by $0.08
|
Revenue of
$3.03M
(2.27% Y/Y)
beats by $1.81M
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial May 7, 2026 8:00 AM EDT
Company Participants
Matthew Philippe - Executive VP &Head of Investor Relations
Michael Davidson - CEO, President & Executive Director
Johannes Jacob Kastelein - Founder, Chief Scientific Officer, Member of Executive Board & Director
Conference Call Participants
Tyler Van Buren - TD Cowen, Research Division
Byunghyun Ahn - Leerink Partners LLC, Research Division
Yuchen Ding - Jefferies LLC, Research Division
James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division
Debjit Chattopadhyay - Guggenheim Securities, LLC, Research Division
Steven Seedhouse - Cantor Fitzgerald & Co., Research Division
Jarwei Fang - Citigroup Inc., Research Division
Yanan Zhu - Wells Fargo Securities, LLC, Research Division
Sebastiaan van der Schoot - Kempen & Co. N.V., Research Division
Srikripa Devarakonda - Truist Securities, Inc., Research Division
Presentation
Operator
Good day, everyone. My name is June, and I will be your conference operator today. At this time, we would like to welcome you to the NewAmsterdam PREVAIL Update Call. [Operator Instructions]
At this time, I would like to turn the call over to Matthew Philippe, Executive Vice President, Head of Investor Relations.
Matthew Philippe
Executive VP &Head of Investor Relations
Thank you, and good morning, everybody. Thanks for joining our call today. I'm excited to have Michael Davidson, CEO; John Kastelein, Chief Scientific Officer; and Ian Somaiya, our Chief Financial Officer, on the call today.
The presentation we'll be discussing is available on our investor site. So please feel free to access it there. However, before we begin, I let Michael share some exciting news. I would like to remind everyone and direct everyone to Slide 2 and remind that this call will contain forward-looking statements within the meaning of federal securities law. These statements may include, but are not limited to, those related to potential clinical benefits of our product
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。